Low Grade Serous Ovarian Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Low Grade Serous Ovarian Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major low grade serous ovarian carcinoma markets reached a value of US$ 179.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 363.7 Million by 2034, exhibiting a growth rate (CAGR) of 6.62% during 2024-2034.

The low grade serous ovarian carcinoma market has been comprehensively analyzed in IMARC's new report titled "Low Grade Serous Ovarian Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Low grade serous ovarian carcinoma (LGSOC) refers to a rare subtype of epithelial ovarian cancer that grows slowly and has a relatively better prognosis compared to other types of ovarian cancer. It is characterized by the presence of small, uniform tumor cells that form glandular structures. The common symptoms of this condition include chronic stomach pain, difficulty eating, bloating, changes to bowel movements, urinary urgency, etc. Individuals suffering from LGSOC may also experience a sudden feeling of fullness, reduced appetite, and pain in the stomach, back, and pelvis. The diagnosis of the ailment typically requires a combination of clinical examination, medical history, and a pelvic test. A CA125 blood workup, which can detect a protein in the body that is a cancer marker, is further utilized for disease detection among patients. The healthcare provider may perform transvaginal ultrasound and computerized tomography scans to rule out other possible causes and confirm a diagnosis.

The rising prevalence of inherited genetic disorders, causing DNA abnormalities, gene variations, and chromosomal damage, is primarily driving the low grade serous ovarian carcinoma market. Furthermore, the increasing incidences of various associated risk factors, such as family history, obesity, past childbirth, pregnancy, advancing age, etc., are also augmenting the market growth. Apart from this, the widespread adoption of kinase inhibitors, including pertuzumab, afatinib, trastuzumab, etc., to reduce tumor cells and block disease progression among patients is further creating a positive outlook for the market. Additionally, the emerging popularity of real-time molecular profiling technologies, since they can support the management of the underlying ailment by identifying genetic mutations and other molecular abnormalities that cause LGSOC, is also bolstering the market growth. Moreover, the inflating utilization of cytoreductive surgery and platinum-based chemotherapy which enhance host immunological response, thereby eradicating cancer masses and improving overall survival, is acting as another significant growth-inducing factor. In addition to this, the escalating demand for biomarker testing and sequencing that help in early diagnosis, predict response to therapy, and monitor disease progression is expected to drive the low grade serous ovarian carcinoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the low grade serous ovarian carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for low grade serous ovarian carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the low grade serous ovarian carcinoma market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the low grade serous ovarian carcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the low grade serous ovarian carcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current low grade serous ovarian carcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the low grade serous ovarian carcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the low grade serous ovarian carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the low grade serous ovarian carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of low grade serous ovarian carcinoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of low grade serous ovarian carcinoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of low grade serous ovarian carcinoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with low grade serous ovarian carcinoma across the seven major markets?
What is the size of the low grade serous ovarian carcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of low grade serous ovarian carcinoma?
What will be the growth rate of patients across the seven major markets?

Low Grade Serous Ovarian Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for low grade serous ovarian carcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the low grade serous ovarian carcinoma market?
What are the key regulatory events related to the low grade serous ovarian carcinoma market?
What is the structure of clinical trial landscape by status related to the low grade serous ovarian carcinoma market?
What is the structure of clinical trial landscape by phase related to the low grade serous ovarian carcinoma market?
What is the structure of clinical trial landscape by route of administration related to the low grade serous ovarian carcinoma market?